Prostatype Genomics Valuation
Is PROGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PROGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate PROGEN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PROGEN's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PROGEN?
Key metric: As PROGEN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is PROGEN's PS Ratio? | |
|---|---|
| PS Ratio | 1.9x |
| Sales | SEK 4.12m |
| Market Cap | SEK 7.88m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | -0.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does PROGEN's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.9x | ||
EURI B European Institute of Science | 4.6x | n/a | SEK 4.0m |
APTA Aptahem | 3x | n/a | SEK 7.3m |
GEAN Genetic Analysis | 1x | n/a | NOK 25.6m |
CYXO Cyxone | 3.1x | n/a | SEK 15.8m |
PROGEN Prostatype Genomics | 1.9x | n/a | SEK 7.9m |
Price-To-Sales vs Peers: PROGEN is good value based on its Price-To-Sales Ratio (1.9x) compared to the peer average (2.9x).
Price to Sales Ratio vs Industry
How does PROGEN's PS Ratio compare vs other companies in the SE Biotechs Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 11.8x | 17.8% | |
PROGEN Prostatype Genomics | 1.9x | n/a | US$713.84k |
XBRANE Xbrane Biopharma | 1.5x | 61.1% | US$28.14m |
SPRINT Sprint Bioscience | 1.7x | 27.6% | US$9.55m |
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 11.8x | 44.9% | |
PROGEN Prostatype Genomics | 1.9x | n/a | US$713.84k |
Price-To-Sales vs Industry: PROGEN is good value based on its Price-To-Sales Ratio (1.9x) compared to the Swedish Biotechs industry average (11.8x).
Price to Sales Ratio vs Fair Ratio
What is PROGEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate PROGEN's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
AstraZeneca
UK£154.5b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£1,413.50
7D
-1.8%
1Y
4.5%
PMD Device Solutions
SEK 36.3m
A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.
PMDS
SEK 1.28
7D
-14.7%
1Y
n/a
Swedish Orphan Biovitrum
SEK 99.5b
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.
SOBI
SEK 290.60
7D
-12.4%
1Y
15.7%